TY - JOUR
T1 - Bevacizumab treatment for cancer patients with cardiovascular disease
T2 - A double edged sword?
AU - Pereg, David
AU - Lishner, Michael
PY - 2008/10
Y1 - 2008/10
N2 - Recently, bevacizumab, the novel humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), has shown promising preclinical and clinical anti-cancer activity. However, concerns have been raised regarding a possible increased risk for arterial thrombo-embolic events associated with its administration, especially in patients with pre-existing cardiovascular disease. On the other hand, bevacizumab treatment is associated with an increased bleeding risk that may be augmented by the co-administration of anti-platelet drugs such as aspirin and clopidogrel. In this paper, we present the available data, identify controversies and unresolved issues, and suggest solutions regarding the administration of bevacizumab to cancer patients with cardiovascular disease.
AB - Recently, bevacizumab, the novel humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), has shown promising preclinical and clinical anti-cancer activity. However, concerns have been raised regarding a possible increased risk for arterial thrombo-embolic events associated with its administration, especially in patients with pre-existing cardiovascular disease. On the other hand, bevacizumab treatment is associated with an increased bleeding risk that may be augmented by the co-administration of anti-platelet drugs such as aspirin and clopidogrel. In this paper, we present the available data, identify controversies and unresolved issues, and suggest solutions regarding the administration of bevacizumab to cancer patients with cardiovascular disease.
KW - Bevacizumab
KW - Bleeding
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=53249117268&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehn384
DO - 10.1093/eurheartj/ehn384
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???
C2 - 18762551
AN - SCOPUS:53249117268
SN - 0195-668X
VL - 29
SP - 2325
EP - 2326
JO - European Heart Journal
JF - European Heart Journal
IS - 19
ER -